A US-based KOL at a tertiary academic center discusses the evolving treatment landscape in gastric cancer, with particular focus on the unique patient mix seen in an academic setting versus community practice and how this shapes treatment decision-making across lines. Biomarker-driven treatment selection, the role of re-biopsy in HER2-positive disease, pipeline agents including zanidatamab and emerging bispecifics, and key unmet needs in the perioperative and refractory settings were also discussed.

This interview was conducted on April 10, 2026. 

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.